AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie's immunology franchise remains a key driver of growth, with Skyrizi and Rinvoq continuing to gain market share and exceed analyst expectations. These two drugs are crucial to the company's ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...